Melanoma/Skin Cancer

Top Story

The Wistar Institute marks 125 years of research milestones for cancer, infectious diseases

The Wistar Institute marks 125 years of research milestones for cancer, infectious diseases
January 12, 2018
In the Journals Plus

Toxic effects of immunotherapy ‘a valid concern’ among oncology experts

January 11, 2018
Combining nivolumab with epidermal growth factor receptor tyrosine kinase inhibitors increased the risk for
Cover Story

Pipeline of novel immunotherapies may offer ‘more nuanced approach’ to cancer treatment

HemOnc Today, January 10, 2018
Immunotherapy is increasingly recognized as an important therapeutic modality to treat cancer. Checkpoint inhibitors — six of which have been approved since 2011…
Point/Counter

Is the success of future immunotherapies dependent on biomarkers?

HemOnc Today, January 10, 2018
POINT PD-L1 and tumor mutational burden are two more mature biomarkers that have been assessed in clinical trials and correlated with outcomes. Many other biomarkers are…
More Headlines »
CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Video
Meeting News

VIDEO: Speaker discusses targeted treatment for melanoma

April 19, 2017
More »
Resource Centers
San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium

CME

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed…
More »